Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc.

23 views4 min read

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

Mind Medicine (MindMed)
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO , May 11, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) ("MindMed" or the "Company") is pleased to announce that further to its previously announced offering (the "Offering") on May 5, 2020 and May 6, 2020 , it has fi... Read More...
25 views6 min read

Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips

Mind Medicine (MindMed)
Advances Discovered in Collaboration with University Hospital Basel's Liechti Laboratory and Aims To Enhance Therapeutic Potential of PsychedelicsNEW YORK, April 21, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), in collaboration with University Hospital Basel's Liechti Laboratory, has discovered and filed a patent applica... Read More...
15 views4 min read

MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

Mind Medicine (MindMed)
NEW YORK, April 16, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. 18-MC is a proprietary, orall... Read More...
Joint VentureM & A51 views6 min read

MindMed Acquires Exclusive License to Eight Clinical Trials of LSD, Partners with World-Leading Psychedelic Research Laboratory at University Hospital Basel

Mind Medicine (MindMed)
Multi-year deal gives MindMed access to largest collection of clinical trials & knowhow for LSD psychedelic research including a Phase 2 clinical trial of LSD for the treatment of anxietyBASEL, Switzerland, April 1, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTC: MMEDF), the leading neuro-pharmaceutical company for psychedelic in... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!